Finch Ther­a­peu­tics brings on new CEO, CFO af­ter Jan­u­ary lay­offs and scrap­ping a PhI­II tri­al

Finch Ther­a­peu­tics has had three rounds of lay­offs in the past year and is now go­ing through a lead­er­ship shake­up three months af­ter scrap­ping a Phase III tri­al for one of its mi­cro­bio­me ther­a­pies.

Co-founder Mark Smith will step down as CEO and as a mem­ber of the board on May 15 for Matthew Blis­chak, who will take over as CEO on May 16. The com­pa­ny said in a state­ment that Smith is ex­pect­ed to stay on as a sci­en­tif­ic and strate­gic ad­vi­sor.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER